Great. Hi. Good afternoon, everyone. Welcome to the Jefferies Healthcare Conference. My name is Michel Phaedonos. I'm a VP of Investment Banking here at Jefferies, working in healthcare. I'm here today to moderate this fireside with Renée Aguiar-Lucander, CEO of Hansa Biopharma. We can jump straight to it.
Great.
Fantastic. Renée, to begin, could you please briefly introduce Hansa and explain the problem the company is trying to solve for patients?
Sure. Hansa Biopharma has a novel first-in-class IgG-cleaving platform. These are enzymes that basically cleave all four classes of IgG, both intravascularly and extravascularly. Really what we're addressing are a couple of areas, one being desensitization of highly sensitized patients awaiting kidney transplant. Another area where we generated clinical data as well is in gene therapy, similarly kind of desensitizing patients for these kind of AAV vector delivery systems, where there's also a lot of patients who have high levels of antibodies against. Those are really kind of the two main areas. Then we have a second enzyme from the same platform that we're just taking into a rare neurological disease called Guillain-Barré syndrome, which we hope to start a phase II trial for before the end of the year.
Great. Thank you. You mentioned imlifidase works by rapidly removing the antibodies that can prevent a highly sensitized patient from receiving a donor kidney. Could you explain how it works in practice, and where does it fit within the transplant pathway?
Sure. So, looking at, for example, the clinical trial that we read out end of September last year, these are patients actually that had extremely high levels of antibodies. So, 99.9 kind of it is called a CPRA score of 99.9 or higher, meaning that the probability of them finding a natural match in the donor universe is kind of 0.0% or less. For these patients, what you basically do is you go into their profile in the kind of matching system in the U.S., and you actually delist some of their antigens, because obviously, how else are you ever going to get an organ if you have this issue? You basically go in and kind of synthetically change their profile somewhat, and thereby enabling them to actually get an organ offer.
Once you have that organ offer and the patient, generally, obviously, you would then expect that that would actually still be a positive cross-match because you haven't really changed anything in the patient's actual kind of profile apart from synthetic getting an organ. You then basically give a 15 minute infusion of imlifidase, and within two to six hours after that infusion, you basically will have reduced IgG levels by over 95% from baseline, thereby turning a positive cross-match to a negative cross-match, and thereby enabling this kidney transplant. That's really how it fits in. It's very kind of very, very rapid, very kind of consistent and predictable. And obviously with all of the clinical trials as well as some commercial use, the data that we have is really very consistent across this patient population.
What we do is we do this, and then as kind of antibodies come back over time, these patients are monitored and basically treated with immune suppression the same way as any other kind of transplant patient. And obviously, as you can see those antibodies coming back, it's quite manageable to manage them from low levels. The issue here is obviously you can't really do anything when patients have very high levels of antibodies. That's really kind of how it fits in.
Excellent. Thank you. The next question is around your phase. The ConfIdeS phase III trial produced positive results in highly sensitized kidney transplant patients. What do you see as the most important findings from this study, and what do they tell us about the role or potential role of imlifidase in the U.S.?
This study basically involved 64 patients, 32 patients in each arm. There was an imlifidase arm and a control arm. The control arm was basically practice of medicine. Anything that was actually available to the physicians is what they could use. What we saw in that trial, with a p-value of less than 0.0001, is that actually there are very, very few alternatives, if any, for these patients. If you can imagine these patients, obviously, all of these patients had an organ offer at time of randomization. This might have been the very first time they ever had an organ offer. Despite that, less than 10% of the control arm actually chose to go forward and have a transplantation at the time of randomization.
Only three patients out of 32 went forward with a transplant in the control arm, but actually 27 immediately progressed to a transplant in the imlifidase arm. I think what that shows us really is that there is really no alternative for these. It is a significant unmet medical need, and there is really nothing out there for these patients today that can be used that are this kind of predictable, consistent, and safe. I also think that what we saw is in terms of even those patients who did progress to transplant, whether it was at randomization or later point in the control arm, the actual endpoint was eGFR, so kidney function after 12 months from randomization.
Even on that metric, what we saw is that the kind of levels of kidney function at the patients treated with imlifidase were in the range of kind of 50- 51 mL/min, whilst actually those patients who were treated with kind of alternative experimental approaches, were kind of in the 23% kind of area in terms of those three patients who kind of progressed at randomization. Unfortunately, also the outcomes that we have seen for those patients that are using other experimental approaches have not been encouraging.
Great. Maybe around the potential role in the U.S., is that
Yeah. I think obviously in the U.S., what we have today is that there is obviously over half a million people on dialysis today in the U.S. 100,000 of those approximately are on a wait list, awaiting transplant. Out of those, around 15% is categorized as highly sensitized. That would mean that you have this CPRA score of 80 or above. Obviously, if we look at the core target market that we think imlifidase, if approved, could address, that would probably be those patients around, that have 98 or above in terms of CPRA score. So they have less than a 2% chance to find a match. That is about 7,000 patients or so on the wait list today in the U.S.
I think for us, this really gives that is obviously one core target opportunity. The other one is actually that in today's, there are about 27,000 transplants done each year in the U.S. But out of that, 9,000 kidneys are actually harvested and actually not used in the U.S. Over half of those are categorized and classified as no recipient found, list exhausted. Which basically means that there is a sequential, you have a match automatically, you have to call up that center, you have to see if the team wants to accept that kidney, et cetera. It goes through, it can go through several of these cycles, and at the end of the day, you might end up with actually not being able to use the kidney just for timing reasons.
We also hope that this could actually address, help actually more patients overall get to a transplant which again, I think there has been recent publications in terms of there is a significant health economic benefit in terms of transplant versus dialysis. If you ever have been to dialysis clinic or know anyone on dialysis, you would also know that that is not a pleasant way to spend your life on dialysis. So this another opportunity that we think we have. Thirdly, obviously, what we are hoping to do post a potential approval is also go back to the FDA and have conversations with them around potentially what kind of information and data would they require in order to go into other solid organ type transplants, which then to expand the label.
Those are really some of the opportunities that we see in the U.S., and that is obviously just in the transplant area and not even taking into account some of the potential opportunity in gene therapy.
Thank you, Renée. A similar question around the U.S. The FDA is currently reviewing the imlifidase application, with a PDUFA on December 19, 2026. Without getting ahead of that process, how are you thinking about the opportunity and the practical requirements for bringing the therapy to U.S. patients if approved?
What we have done obviously is we ran this trial that we spoke about, the ConfIdeS trial, in 25 centers in the U.S. Those 25 centers represent approximately 25% of the volume of all kidney transplants carried out in the U.S. So, in the U.S., there are about 100 centers that represent 80% of the volume, and a total number of about 200 centers that actually carry out kidney transplantation. So it's an extremely focused and small call point from that perspective. And what we've had is, we've built up a full leadership team in the U.S., and we've had both in the field, both medical affairs and market access.
People who's actually been able to go to these hospitals and try and understand how they operate today, how do they manage highly sensitized patients today, what would be required potentially from us to try and help them, which of these hospitals are already very well-equipped to deal with this, et cetera. So, we have a very good idea of what the target market looks like. And so we really have, again, for U.S. launch, we think this is very capital efficient because of the very tight call point. We would expect to have maybe 15 or so commercial account managers to address this. So I think the U.S. operation, when it's fully staffed, would be 50 - 55 people. We're about 35 people there today. And so I think the team is very experienced.
They've done a lot of these things before. And so I think we're extremely well-positioned to be able to launch this in the U.S. and have a very robust launch based on all of the preparations and based on all the expertise that we have in that team.
Great. Thank you. Changing geography here. In Europe, the PAS study reported positive one-year outcomes and supported the planned move from conditional to full marketing authorization. What has the European experience taught you about patient identification, treatment center adoption, and the role of imlifidase in clinical practice?
Yeah, the PAS study basically was a kind of confirmatory trial, but to most intents and purposes, it was really kind of a phase III trial. Because previously to that trial, there had only been about an open-label single-arm study with about 16 patients that had been kind of presented to EMA. EMA really wanted a much larger subset of patients or kind of number of patients to go through the treatment. Also in Europe, there had been very, very little involvement of clinicians. There are only two sites actually in Europe that participated in that trial, and the rest was actually kind of conducted in the U.S. So the PAS data was extremely consistent with what we saw from the ConfIdeS study.
50 patients being transplanted, again, looking at kind of graft survival overall survival, et cetera, at 12 months and any eGFR levels. I think what we saw was very consistent with the ConfIdeS, and also consistent with the data where we collected in a non-kind of statistical comparative group, also with those kind of patients who were going through non-highly sensitized kind of donor transplants at the same sites in the Europe. So we basically had very similar outcomes in terms of all of those metrics, which I think is also very encouraging. We are targeting to file for full approval in Q4, so this quarter, which we are on track to do, with then a view to kind of convert that from a conditional approval to a full approval, which we would expect.
I think Europe is a very different kind of setup from the U.S., not only because of the fragmentation and the other issues around reimbursement or anything else in Europe, but actually because in Europe, it was a very kind of the wrong, unusual way around in terms of actually kind of getting approval on a very, very small data set, and then for everyone really to get that clinical experience in that kind of confirmatory trial as well as that data, which we just read out in June.
I think that obviously there are a couple of things that we can certainly learn from Europe, but I think that it's not really. I think that the drug in Europe today, based on the ConfIdeS data and the data we read out from PAS, will probably go through some kind of relaunch really on the basis of having a much, much more substantial set of data points now that actually that kind of trial has concluded. My expectation would be that you would kind of see a significant kind of different commercial appetite in Europe post the data. I think this is something that we're certainly kind of seeing in the U.S., where we've had a lot of ad boards, we've had a lot of interactions with physicians, and I think there's a real high level of interest for the drug.
I think the data that we've been able to now present in different kind of conferences has been very, very well received and very well understood by the transplant community. We're excited about being able to kind of launch it commercially in the U.S. hopefully.
Fantastic. Thank you. The next question is beyond kidney transplantation. Where else could Hansa's cleaving technology have an important role, and which parts of the broader pipeline should investors be paying the most attention to?
I would say obviously, in terms of other kind of solid organ transplants, I think that is an opportunity that we consider something that we definitely want to pursue. If you look at other kind of the whole, the category of other kind of solid transplant, that market as a whole is probably approximately the same size as the kidney market. So that's another significant opportunity for us. I would also say that the gene therapy space is something that we're going to explore over the next 12 months as kind of gene therapies kind of mature and more of them go into later stage trials and commercial availability in those kind of rare disease spaces to the extent that you are unable to kind of access anywhere from 10%-40% of your population.
That is something where we believe that imlifidase could have a role to play potentially. This is something that we're also kind of looking into and we'll be able to kind of have a better view in terms of how we see that landscape developing and how we see kind of imlifidase potentially having a role there. I think the other area is obviously in our kind of more the neurological rare disease space in terms of our second enzyme, taking that into clinical trial. I think hopefully, we'll start that hopefully before the year end, and I think that could be another really exciting opportunity.
Excellent. Thank you. Moving to the final question. Which aspects of the Hansa story do you think investors understand least well today, and what are the key publicly disclosed milestones they should watch over the next 12 - 18 months?
I think, well, in terms of the obvious milestone, which is coming up in about a month, is obviously the PDUFA date. That I think is going to be kind of a significant value inflection point for the company, as well as then kind of the subsequent commercial launch. Again, I think we have an extremely experienced, talented team, so I have great confidence in the fact that we'll be able to kind of roll that out into the U.S. market. I think apart from that PDUFA date and kind of then I would say from a commercial perspective, I would say that this is obviously, it's an inpatient procedure, and so there are some logistical and technical things of just getting into the hospital market.
I would say that I would not suggest that the first three months is a fantastic judgment of how this launch is going to look. I think that looking at the kind of over the first six to nine months, I think is going to be a much more relevant period to kind of assess the launch for the company, simply because of these kind of intricacies and technicalities in the hospital market. I think the other kind of things that obviously we're looking forward to is kind of some of that, hopefully we'll see some potential collaborations in gene therapy. We hope that's going to be something that we can generate, as well as obviously just the recruitment of patients into our phase II trial.
As well as obviously just the full approval, I think we'll obviously see hopefully also publications of the data around these trials come to market. That I think will be another really kind of, for kind of development of the market and for understanding of the drug, I think that would also be very significant events. I think in terms of what kind of may not be as well understood, I think it's the overall kind of market opportunity that we have in front of us. I think what we've really shown in our phase III is that there is really no true kind of standard of care out there. I think there's a very significant unmet medical need. There are really no kind of late-stage clinical trials either in Europe or in the U.S. in the kidney transplant space.
I think both the kidney kind of transplant area, potentially the larger kind of transplant area, as well as the gene therapy, I think is really presenting the company with a very, very significant market opportunity, which is kind of my job to kind of try to continue to explain and discuss and hopefully get more and more investors on side to understand this. I do think that in the transplant, there's been very few novel drugs launched into transplant. I think the last novel drug approved was actually 2015. So I do not think that transplant physicians are spoiled with having lots of new kind of drugs that's actually been tried in their setting.
I think that this may not be a market that investors completely understand or are familiar with, but I do think as we kind of progress and develop the story, I hope to be able to address that.
Fantastic. Renée, thank you very much. Wishing everyone a good conference then.
Thank you.